Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer
Christopher McGuigan, Cardiff (GB); Jan Balzarini, Heverlee (BE); Magdalena Slusarczyk, Cardiff (GB); Blanka Gonczy, Cardiff (GB); and Paola Murziani, Cardiff (GB)
Assigned to Nucana plc, Edinburgh (GB)
Filed by Nucana plc, Edinburgh (GB)
Filed on Jan. 11, 2023, as Appl. No. 18/095,937.
Application 18/095,937 is a continuation of application No. 17/223,241, filed on Apr. 6, 2021, granted, now 11,559,542.
Application 17/223,241 is a continuation of application No. 16/021,103, filed on Jun. 28, 2018, granted, now 10,993,957, issued on May 4, 2021.
Application 16/021,103 is a continuation of application No. 15/489,884, filed on Apr. 18, 2017, granted, now 10,022,390, issued on Jul. 17, 2018.
Application 15/489,884 is a continuation of application No. 14/943,555, filed on Nov. 17, 2015, granted, now 9,655,915, issued on May 23, 2017.
Application 14/943,555 is a continuation of application No. 14/560,097, filed on Dec. 4, 2014, granted, now 9,221,866, issued on Dec. 29, 2015.
Application 14/560,097 is a continuation of application No. 14/000,682, granted, now 8,933,053, issued on Jan. 13, 2015, previously published as PCT/GB2012/050457, filed on Feb. 29, 2012.
Claims priority of application No. 1103582 (GB), filed on Mar. 1, 2011; and application No. 1105660 (GB), filed on Apr. 1, 2011.
Prior Publication US 2023/0165886 A1, Jun. 1, 2023
1. A method of treating cancer comprising administering intravenously to a human patient in need thereof an effective dose of 5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate, or a pharmaceutically acceptable salt thereof;
wherein the compound is provided in a sterile aqueous solution or suspension, or
wherein the compound is presented as a liposome formulation; and
wherein the cancer is responsive to 5-fluorouracil or 5-fluoro-2′-deoxyuridine.